复方血栓通胶囊联合康柏西普治疗老年黄斑变性的临床研究

目的 探讨复方血栓通胶囊联合康柏西普治疗老年黄斑变性的临床疗效。方法 选取2016年1月—2020年12月河南大学第一附属医院收治的200例黄斑变性患者，按照随机抽样法将所有患者分为对照组与治疗组，每组各100例。对照组患者使用康柏西普眼用注射液。治疗组在注射康柏西普眼用注射液后第2天口服复方血栓通胶囊，3粒/次，3次/d，连续用药3个月。两组患者康柏西普注射每月1次，连续3次，并进行每月定期随访1次。观察两组的临床疗效，比较两组眼血液动力学指标和血清相关因子水平的变化情况。结果 治疗后，治疗组总有效率是90.0%，显著高于对照组的78.0%（P<0.05）。治疗后，两组收缩期峰值流速（PSV）、舒张末期流速（EDV）显著升高，但阻力指数（RI）、黄斑中心视网膜厚度（CMT）显著降低（P<0.05）；治疗后，治疗组眼底血流动力学指标改善优于对照组（P<0.05）。治疗后，两组血清C-反应蛋白（CRP）和血管内皮生长因子（VEGF）水平显著降低（P<0.05）；治疗后，治疗组血清CRP、VEGF水平低于对照组（P<0.05）。结论 复方血栓通胶囊联合康柏西普治疗老年黄斑变性具有较为理想的疗效，可有效改善血清CRP、VEGF水平及眼底血流动力学指标，具有较高的临床应用价值。

Clinical study of Compound Xueshuantong Capsules combined with conbercept in treatment of age-related macular degeneration

Objective To investigate the effect of Compound Xueshuantong Capsules combined with conbercept in treatment of age-related macular degeneration. Methods A total of 200 patients with macular degeneration admitted to the First Affiliated Hospital of Henan University from January 2016 to December 2020 were selected and divided into control group and treatment group according to random sampling method, with 100 cases in each group. Patients in the control group were received Conbercept Ophthalmic Injection. Patients in the treatment group were po administered with Compound Xueshuantong Capsules on the second day after injection of Conbercept Ophthalmic Injection, three grains/time, three times daily, the drug was administered continuously for 3 months. Patients in both groups were injected with compaxerib once a month for 3 consecutive times. The clinical efficacies of two groups were observed, and the changes of ocular hemodynamic indexes and serum factor levels were compared between the two groups. Results After treatment, the total effective rate of treatment group was 90.0%, significantly higher than 78.0% of control group (P<0.05). After treatment, peak systolic flow rate (PSV) and end diastolic flow rate (EDV) were significantly increased, but resistance index (RI) and central macular retinal thickness (CMT) were significantly decreased in both groups (P<0.05). After treatment, the improvement of fundus hemodynamic indexes in the treatment group was better than that in the control group (P<0.05). After treatment, the levels of serum C-reactive protein (CRP) and vascular endothelial growth factor (VEGF) in two groups were significantly decreased (P<0.05). After treatment, serum CRP and VEGF levels in the treatment group were lower than those in the control group (P<0.05). Conclusion Compound Xueshuantong Capsules combined with conbercept has a relatively ideal therapeutic effect in treatment of age-related macular degeneration, and can effectively improve the levels of serum CRP, VEGF and fundus hemodynamics, which has a high clinical application value.